Childhood acute lymphoblastic leukemia
Relapsed and refractory disease after frontline cure rates: blinatumomab, inotuzumab and CD19 CAR-T cells.
Registry changes (new trials, status, phase, endpoint and readout-date changes, results) come from the OncoSignal store, last verified against ClinicalTrials.gov 2026-11-11 08:26 UTC.
- PaperEx Vivo Thrombin Generation Assessment of Four Anticoagulants in Children with Acute Lymphoblastic Leukemia.
Leader A, Wolach O, Gavrieli B et al. Pediatric hematology and oncology.
- PaperMenin inhibitors in acute leukemia: Advances and future directions.
Nasiri A, Saleh MFM, Alfayez M et al. Hematology/oncology and stem cell therapy.
- PaperResistance mechanisms and translational bottlenecks in CAR-T cell therapy for pediatric acute lymphoblastic leukemia: a perspective.
Xu J, Sui L, Yang W et al. Frontiers in immunology.
- PaperAdverse Family Outcomes in Children With B-Cell Acute Lymphoblastic Leukemia From the Multicenter Trial Children's Oncology Group AALL0932.
Rodwin RL, Kairalla JA, Hibbitts E et al. Journal of the National Comprehensive Cancer Network : JNCCN.
- PaperBlinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia.
Schrappe M, Locatelli F, Valsecchi MG et al. The New England journal of medicine.
A phase advance is an asset's first trial at a higher phase than any earlier trial of the same asset in this indication. Readout due means the registry's primary completion date has passed; it is not a disclosure.